PDYNHIGH SIGNALFINANCIAL10-K

PDYN shows concerning operational deterioration with declining revenue, widening losses, and worsening cash burn despite a stronger balance sheet from apparent equity financing.

The company appears to be in a challenging transition phase, with revenue declining meaningfully while operating losses and cash burn have both worsened by over 20%. The removal of language about commercialization delays and shift to discussing broader "AI/ML Foundational Technology" suggests potential pivoting in strategy or market positioning.

Comparing 2026-03-05 vs 2025-02-20View on EDGAR →
FINANCIAL ANALYSIS

PDYN's balance sheet strengthened significantly with total assets growing 70% to $95.7M and total liabilities declining 68% to $21M, likely reflecting new equity financing given the 32% increase in outstanding shares. However, operational performance deteriorated notably with revenue falling 33% to $5.2M while operating losses widened to -$32.4M and operating cash flow worsened to -$27.6M. The combination of declining revenue and increasing R&D spend suggests the company is investing heavily in development while struggling with current market traction.

FINANCIAL STATEMENT CHANGES
Total Assets
Balance Sheet
+70.1%
$56.3M$95.7M

Asset base grew 70.1% — expansion through organic growth, acquisitions, or capital deployment.

Total Liabilities
Balance Sheet
-68%
$65.8M$21.0M

Liabilities reduced 68% — deleveraging improves balance sheet strength and financial flexibility.

Cash & Equivalents
Balance Sheet
-41.6%
$31.2M$18.2M

Cash declined 41.6% — significant cash burn or deployment; verify adequacy of remaining liquidity runway.

Revenue
P&L
-32.6%
$7.8M$5.2M

Revenue declined 32.6% — significant demand weakness or market share loss warrants investigation.

Current Liabilities
Balance Sheet
+27.8%
$4.4M$5.7M

Current liabilities rose 27.8% — increased short-term obligations, watch current ratio.

R&D Expense
P&L
+23.6%
$10.4M$12.9M

R&D investment increased 23.6% — signals commitment to future product development, though near-term margin impact.

Current Assets
Balance Sheet
+23%
$42.7M$52.6M

Current assets grew 23% — improving short-term liquidity or inventory/receivables build.

Operating Cash Flow
Cash Flow
-22.1%
-$22.6M-$27.6M

Operating cash flow softened — monitor whether temporary working capital timing or structural deterioration.

Operating Income
P&L
-20.4%
-$26.9M-$32.4M

Operating profitability softening — costs rising faster than revenue, watch for margin recovery plan.

LANGUAGE CHANGES
NEW — 2026-03-05
PRIOR — 2025-02-20
ADDED
As of February 20, 2026, the registrant h ad 46,494,865 s hares of Common Stock, $0.0001 par value per share, outstanding.
Management's Discussion and Analysis of Financial Condition and Results of Operations 50 Item 7A.
Our AI/ML Foundational Technology and other technologies and products are technologies and the timing and magnitude of revenues from customers is uncertain.
We have no previous history with our licensing sales model for our software products.
Some of our products require hardware components, and we are dependent on our suppliers, some of which are currently single, sole or limited source suppliers.
+7 more — sign up free →
REMOVED
As of February 11, 2025, the registrant h ad 35,219,701 s hares of Common Stock, $0.0001 par value per share, outstanding.
Management's Discussion and Analysis of Financial Condition and Results of Operations 48 Item 7A.
Successful commercialization of our AI/ML Foundational Technology and related products may be delayed beyond our current expectations and therefore product availability to customers, customer acquisition and receipt of software licensing revenue could be delayed.
Our anticipated revenues are expected to be primarily derived from the licensing of our AI/ML software products for the foreseeable future.
Our AI/ML Foundational Technology and related products are new technologies and the timing and magnitude of revenues from customers is uncertain.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →